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Hepatitis viruses are the leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Since currently available treatment
options against these viruses are limited, there is a need for development of alternative therapies. In this minireview, we concentrate on three
hepatitis viruses—hepatitis C virus, hepatitis B virus, and hepatitis delta virus and discuss how RNA interference (RNAi) has been utilized
against them. RNAi is a process by which small double-stranded RNA can effectively target a homologous RNA sequence for degradation by
cellular ribonucleases. Though RNAi was exploited in the beginning for down-regulating cellular genes, it has recently been demonstrated
that this process is equally effective against many types of human and animal viruses including the hepatitis viruses. Both synthetic small-
interfering RNAs (siRNAs) and plasmid-based siRNA expression systems have been useful in suppressing the hepatitis viruses. Though this
new approach looks promising, problems of nonspecific effects and delivery may need to be addressed before the full therapeutic potential of
RNAi against viral infections in patients is realized.
D 2004 Elsevier Inc. All rights reserved.Keywords: RNA interference; Viral hepatitis; dsRNAIntroduction
RNA interference (RNAi) is a process of sequence-
specific post-transcriptional gene silencing initiated by dou-
ble-stranded RNA (dsRNA). This phenomenon was first
observed in the nematode Caenorhabditis elegans (Fire et
al., 1998) and is conserved in mammalian cells. RNAi-
dependent silencing in C. elegans can be initiated through
dsRNA injection, soaking of worms in dsRNA, or feeding
the worms with dsRNA-producing bacteria. After delivery
of long dsRNA to C. elegans, it is subsequently processed
into 21–25 bp functional small interfering RNA (siRNA) by
an enzyme called Dicer that belongs to the RNase III family
(Bernstein et al., 2001). siRNAs are incorporated into an
enzyme complex RISC (RNA-induced silencing complex),
which upon activation unwinds the siRNA. This unwound
siRNA is used by RISC for selecting the target RNA by0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: agartel@uic.edu (A.L. Gartel).Watson–Crick base-pairing, which is later degraded in the
region of homology directed by the original siRNA (Elba-
shir et al., 2001).
The process of RNAi has been extended recently to
mammalian cells with a few modifications. Unlike in C.
elegans, long dsRNA cannot be used in mammalian sys-
tems because they evoke a nonspecific interferon (IFN)
response that activates protein kinase PKR (Balachandran
et al., 2000). But this problem has been circumvented
recently by using short RNA duplexes of length approxi-
mately 21 bases with 2- or 3-nucleotide (nt) 3V-end over-
hangs. Elbashir et al. (2001) successfully used this method
against endogenous lamin A/C genes and tumor suppressor
p53. Since then this method has been used to silence a
large number of endogenous mammalian genes (for a
review, see Hannon, 2002; McManus et al., 2002; Paddison
and Hannon, 2002; Zamore, 2001).
Apart from silencing of cellular genes, RNAi is a very
attractive option for suppressing viral RNA. In fact in plants,
RNAi is a natural defense mechanism against RNA of
invading viruses. The presence of a double-stranded RNA
intermediate during the replication of the virus is thought to
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successfully used against several viruses in mammalian cells.
Bitko and Barik (2001) used siRNA to silence the mRNAs
produced by the respiratory syncytial virus (RSV), a negative
strand virus that causes a form of respiratory disease. How-
ever, authors of this work could not inhibit the full-length
viral genomic strand that might be due to the fact that the
RNAwas associated with structural proteins. Recently, HIV
has also been targeted in several studies. In several in vitro
models, siRNAs were directed either against HIV RNA
(Capodici et al., 2002; Coburn and Cullen, 2002; Hu et al.,
2002; Jacque et al., 2002; Lee et al., 2002; Novina et al.,
2002; Park et al., 2002; Surabhi and Gaynor, 2002; Yama-
moto et al., 2002) or were targeted against RNA encoding for
the primary HIV-1 co-receptor, CXCR4/CCR5 (Cordelier et
al., 2003; Martinez et al., 2002; Qin et al., 2003). RNAi has
also been used against several other viruses includingDengue
virus (Adelman et al., 2001, 2002; Caplen et al., 2002), flock
house virus (FHV) (Li et al., 2002), rhesus rotavirus (RRV)
(Dector et al., 2002), Semliki forest virus (SFV) (Caplen et
al., 2002), influenza virus (Ge et al., 2003), and poliovirus
(Gitlin et al., 2002).
It is also interesting to note that a few viruses have
evolved counter-defenses against RNAi. It has been dem-
onstrated that hepatitis delta virus (HDV) RNA is resistant
to Dicer action (Chang et al., 2003). In Drosophila cells, it
has been shown that FHV suppresses RNAi (Li et al.,
2002). More recently, it was found that E3L and NS1
protein products encoded by the mammalian vaccinia and
influenza viruses can suppress RNA silencing (Li et al.,
2004). Also in plants, it is known that proteins such as 2b
of Cucumovirus, AC2 of Geminivirus, HcPro of Potyvirus,
P1 of Sobemovirus, and p19 of Tombus virus suppress
gene silencing (Brigneti et al., 1998; Kasschau and Car-
rington, 1998; Vaucheret et al., 2001; Voinnet et al., 1999).
The mechanisms of these processes are being unraveled
gradually. For example, the precise structural basis under-
lying the sequence-independent recognition and sequestra-
tion of 19–21 nt siRNAs by p19 of Tombus virus has been
demonstrated recently by X-ray crystallography (Ye et al.,
2003).Fig. 1. Targets that have been used against HCV. (A) Organization of protein codin
consist of C, E1, and E2, the nonstructural proteins are NS2, NS3, NS4A, NS5
nonstructural category. (B) Schematic representation of the subgenomic replicon
starting from C until NS2 have been removed and instead replaced with a Neomy
used by various groups are indicated by downward arrow.RNAi against hepatitis C virus
Hepatitis C virus (HCV) is a member of Flaviviridae
viruses that replicate mainly in the liver of infected patients.
HCV is classified into six major genotypes differing more
than 30% from each other in their nucleotide sequence. The
prototype strain of HCV genotype 1a is found predominant-
ly in the US and Northern Europe, and genotype 1b initially
found in Japan now has worldwide distribution. HCV
possesses a positive-strand RNA of about 9.6 kb consisting
of the 5V untranslated region (5V-UTR), the open reading
frame (ORF), and the 3V-UTR (Fig. 1). Because the HCV
genome is a single-stranded RNA that serves also as a
messenger RNA, it is an appealing target for developing
RNAi-based therapies.
The 5V-UTR is a 341-nucleotide (nt) sequence that is
highly conserved even between the most distantly related
HCV subtypes. The ORF produces a polyprotein that can
subsequently be processed into at least 10 different pro-
teins including a capsid (core) protein, two envelope
proteins (E1 and E2), and nonstructural proteins (NS2,
NS3, NS4, NS5A, and NS5B) (Fig. 1A). The NS5B
protein is an RNA-dependent RNA polymerase (RdRP)
and is the key component in HCV replication. It has been
shown that NS5B associates with NS3 and NS4A to
produce a negative-strand copy of the RNA genome,
which in turn can give rise to several positive-strand
RNA copies.
There are no vaccines available against HCV. Currently,
the favored therapy for HCV infection is the use of PEG-
interferon-a in combination with ribavirin. Over the last
decade this therapy led to sustained virologic response of
40–80% of patients dependent on HCV genotype. Very
recently, a small molecule (BILN 2061) inhibitor of NS3
protease has been shown to be more efficient than either
interferon or ribavirin in restricted clinical trials of human
patients (Lamarre et al., 2003). But it is too early to adopt this
in standard therapy against HCV. Much of this struggle
against HCV is due to its genetically heterogeneous nature
coupled with the existence of quasispecies. Quasispecies are
distinct but closely related variants of the virus that circulateg regions in the HCV RNA genome is shown. While the structural proteins
A, and NS5B. At present, it is not known if p7 belongs to structural or
that has been used in some studies described in the text is shown. Regions
cin resistance gene and the EMCV IRES. The target regions that have been
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error rate of NS5B gene-coded RNA-dependent RNA poly-
merase, which gives significant advantage to HCV survival.
The 5V-UTR region seems to be subjected to much stricter
conservation than other regions of the HCV genome. For
example, the sequences between 30 and 170 nt appear to be
very much conserved between different quasispecies of HCV
1b genotype (Soler et al., 2002). Because RNA interference
(RNAi) technology is very sensitive to single mismatches
between siRNA and target sequences (Shi, 2003), the 5V-
UTR appears to be the best target for silencing HCV.
Lack of in vitro cell culture models had been a major
handicap for HCV research. But recently, subgenomic
replicon systems for HCV have been developed (Fig. 1B)
(Blight et al., 2000; Lohmann et al., 1999). These replicons
have adaptive mutations that aid them to replicate efficiently
in cell culture. They also lack the structural genes and so
cannot produce active viral particles. Using HCV subge-
nomic replicon system, it has been shown recently that
synthetic dsRNA can inhibit HCV RNA replication in cell
culture. The specific targets on the HCV genome used in
these studies are as shown in Table 1.
Seo et al. (2003) used a version of the HCV RNA
subgenomic replicon that has a Neomycin resistance gene
for selection and a luciferase gene for monitoring the levels
of replicon expression. A reduction (85–90%) in the levels
of luciferase was observed if cells were transfected with
siRNAs specific for either the 5V-UTR or the luciferase,
whereas nonspecific control siRNAs or siRNAs with three
nucleotide mismatch to the luciferase target failed to show
any reduction. To confirm that siRNAs do not produce
cellular toxicity, they also measured cellular ATP levels
and found them to be unchanged between transfected and
mock-transfected cells.
Kapadia et al. (2003), using a subgenomic replicon
system derived from HCV genotype 1b and siRNAs against
NS3 and NS5B, showed 5.7- and 8.3-fold inhibition,
respectively, as measured by real-time PCR 2 days after
transfection. The levels of NS3 and NS5B proteins were
found to be unchanged after 2 days as measured by Western
Blot analysis, but started decreasing after day 4, suggesting
that these proteins have a relatively long half-life. They also
compared the extent to which HCV RNA replication wasTable 1
Different targets that have been used to silence HCV
Authors Target sequence
Seo et al. (2003) 5V GUACUGCC
Kapadia et al. (2003) 5V AAUGGCGU
5V AAGGUCAC
Randall et al. (2003) 5V AACCUCAA
5V AAGGUGCU
Wilson et al. (2003) 5V GGAGAUGA
5V GACACUGA
Yokota et al. (2003) 5V GGUCUCGU
Radhakrishnan and Gartel (in preparation) 5V GCGTCTAGinhibited by RNAi and IFN treatment and found that
siRNAs inhibited approximately 3-fold better than IFN
and that the antiviral effect of siRNA is independent of IFN.
Randall et al. (2003), using a similar RNA replicon
system, demonstrated about 5-fold decrease in 12 h and
an 80-fold decrease in 96 h in HCV RNA levels as
measured by real-time PCR when siRNAs against 5V-UTR
were used. This level of total HCV RNA was still main-
tained after 8 days. The vast majority of the cells were cured
of HCV RNA and protein beyond detectable levels by
immunofluorescence with antibodies against NS5A. The
number of G418-resistant colonies in siRNA-treated cells
was dramatically decreased, supporting the conclusion that
siRNAs mediate the clearance of replicating HCV RNA in
this system. This work also showed high specificity of
RNAi silencing of HCV replication because siRNAs that
differed from the target sequence by only 3 nt failed to
mediate suppression.
Wilson et al. (2003) selected both their siRNA targets
against NS5B and showed about 90% reduction in HCV
RNA levels 72 h post-transfection using Northern blot
analysis. Also at this point, the nonstructural proteins
NS3 and NS5B were below detectable levels as measured
by immunoblotting. Next they produced siRNAs in a
plasmid-based expression system, which expressed the
sense and antisense strand of siRNA separately. Cells
expressing siRNA were then selected and were challenged
with HCV subgenomic RNA by electroporation. Three
weeks later they found 70% less G418-resistant colonies
in siRNA-expressing cells relative to control, suggesting
that long-term suppression by RNAi may be achieved by
this method.
Yokota et al. (2003) chose five targets against 5V-UTR
and found that the most efficient siRNA, siRNA-331, sup-
pressed HCV replication by 81% at a concentration of 2.5
nM and the suppression rate increased to 94% at 125 nM.
On the basis of these results, they constructed DNA-based
vectors for expressing siRNA-331. They either used a
tandem type vector, where sense and antisense sequences
were placed separately under the U6 promoter, or a stem-
loop type vector, where the 3V end of the sense sequence and
the 5V end of the antisense strand are connected by a 9-nt
loop sequence and again placed under the control of U6Target location
UGAUAGGGUGC 3V 5V-UTR
GUGUUGGACUGUC 3V NS3
CUUUGACAGACUG 3V NS5B
AGAAAAACCAAACTT 3V 5V-UTR
UGUGGAUAUUUUGTT 3V NS4B
AGGCGAAGGCGUCTT 3V NS5B
GACACCAAUUGACTT 3V NS5B
AGACCGUGCACTT 3V 5V-UTR
CCATGGCGTTAGTATGAGTGT 3V 5V-UTR
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replication, but the stem-loop type was more efficient than
the tandem type.
We were able to achieve complete suppression of HCVas
determined by RT-PCR in cells harboring the replicon by
stably expressing short hairpin RNA (shRNA) from a VA1
fusion construct (Table 1; Radhakrishnan and Gartel, in
preparation). VA1 is an adenoviral gene that has been used
before for expressing ribozymes (Cagnon and Rossi, 2000)
and more recently for shRNAs (Cordelier et al., 2003), both
targeting the endogenous CCR5 gene as a strategy against
HIV. The VA1–shRNA fusion transcripts are primarily
cytoplasmic (Cagnon and Rossi, 2000), which is an impor-
tant advantage because the process of RNA interference is
believed to be restricted to the cytoplasm (Zeng and Cullen,
2002).
These data suggest the use of RNAi to inhibit HCV is
feasible in a replicon system and selection of the targets
may be easily done in this system. In addition, these data
imply that target cells for HCV infection contain all the
functional components that are necessary for RNAi and at
this time it is not clear why HCV does not induce RNAi
response during normal infection. One possibility is thatFig. 2. Targets that have been used against HBV. The + and  DNA strands of
shown around the DNA. Four outer circles represent the four different transcripts
groups are represented by arrows. Some of the targets are effective against multiple
be able to knock down all transcripts because the poly A signal is common to alHCV may inhibit Dicer-dependent cleavage of longer
dsRNAs into approximately 21-nt siRNAs in vivo (Randall
et al., 2003; Seo et al., 2003).
RNAi has also been shown to be effective in silencing
HCV NS5B gene expression in vivo in adult mice. HCV
NS5B gene was fused with a luciferase gene and expressed
in mouse liver (McCaffrey et al., 2002). Naked siRNAs or
siRNAs expressed from plasmids, designed against HCV
NS5B gene, were delivered into the livers of mice by
hydrodynamic transfection method and luciferase expres-
sion was measured. While the chemically synthesized
siRNA reduced luciferase expression by 75%, the plas-
mid-based siRNA was able to achieve a 98% knockdown
(McCaffrey et al., 2002).RNAi against hepatitis B virus
Hepatitis B virus (HBV) belongs to the Hepadnavirus
family that predominantly infects the liver. Though vaccines
have been available for quite some time, it is estimated that
every year approximately a million people die from HBV-
related diseases worldwide. A number of patients withHBV are shown in the center. The various open reading frames (ORFs) are
that are produced by HBV. Various targets that have been used by different
transcripts. For example, an siRNA targeted at the polyadenylation site will
l four transcripts.
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hepatocellular carcinoma (HCC) (Hollinger FB, 2001). The
HBV genome is a 3.2-kb partially double-stranded DNA
(Fig. 2) that has a core gene, which encodes for precore (pre
C or HBeAg) and core (also-called C or HBcAg), the
polymerase gene, which gives rise to reverse transcriptase
(RT) (also-called polymerase or P), the surface protein gene,
which codes for preS1, preS2, and S (also referred to as
HBsAg), and the X gene, which gives rise to X protein. Four
different mRNAs that code for the above-described proteins
are produced from the HBV DNA that are of sizes 3.5, 2.4,
2.1, and 0.7 kb, respectively (Ganem and Varmus, 1987).
The 3.5-kb transcript, in addition to coding for the preC and
HBcAg, also serves as a template for reverse transcription.
At least two different treatment options have been con-
sidered for antiviral therapy of chronic hepatitis B infection.
The first is the use of interferon-a that has been found to be
effective only in limited cases (Lee, 1997). The other ap-
proach is to use nucleoside analogs such as lamivudine
(3TC), adefovir, famciclovir, and penciclovir. Though these
agents successfully reduce viral loads to undetectable levels,
sustained virologic responses have been less than satisfactory
(Liaw, 2002). Alternative strategies are therefore necessary to
combat this disease. Again, RNA interference is an attractive
option and its efficacy against HBV replication has been
demonstrated recently by several groups as discussed below.
The major targets used in these studies are summarized in
Table 2.
Konishi et al. (2003) were able to inhibit viral replication
by using chemically synthesized siRNA in a human hep-
atoblastoma cell line that constitutively produces HBV-
infectious particles. The efficacy as measured by the secre-
tion of HBsAg into culture media varied with the target
chosen—78% with HBV-specific polyadenylation region as
the target and 42% if the target was the surface region. This
shows that target selection plays an important role in the
success of RNAi process; but no systematic method is
available yet to predict which targets would be moreTable 2
Different targets that have been used against HBV
Authors Target sequence
Konishi et al. (2003) 5V ACCCTTAUAAAGA
5V GCTGTGCCTTGGGT
5V TACCGCAGAGTCTA
Hamasaki et al. (2003) 5V CATTGTTCACCTCA
Ying et al. (2003) 5V AAGACCTAGTCAG
Shlomai and Shaul (2003) 5V GATCAGGCAACTAT
5V GGTCTTACATAAGA
Klein et al. (2003) 5V AAGCCTTAGAGTC
5V AATTTGTTCAGTGG
McCaffrey et al. (2003) 5V CTCAGTTTACTAGT
5V CCTAGAAGAAGAA
Giladi et al. (2003) 5V CATCACATCAGGAT
5V CCTCCAATCACTCA
5V CCAGTACGGGACC
5V GTCTGTACAGCATCeffective than the others. Random siRNAs used as a control
were found to be ineffective demonstrating the remarkable
specificity of the RNAi mechanism.
Hamasaki et al. (2003), using siRNA against the core
region of HBV co-transfected with the full-length HBV
DNA into Huh-7 and HepG2 cells, showed that HBeAg
levels in the cell culture medium decreased about 5-fold.
Also, a Southern blot for the levels of replication intermedi-
ates showed a decrease when compared to control siRNAs
against GFP.
Ying et al. (2003) used two different inducible cell
lines—one that produces wild-type HBV, while the other
produces lamivudine-resistant HBV. They were able to
show a dose-dependent reduction in replication as assessed
by real-time quantitative PCR in both cell lines when
siRNAs against the core region were used.
Shlomai and Shaul (2003) used a plasmid-based RNAi
approach against HBV. Here, the short hairpin RNA
(shRNA) was expressed under the control of H1 RNA
promoter from a plasmid. The targets were chosen on the
Core and X genes. Using the core and X gene expression
vectors along with the RNAi constructs, they were able to
show a significant reduction in the levels of these proteins
as estimated by Western blots. The specificity of these
siRNAs was demonstrated by using sequences with muta-
tions that failed to suppress expression of these proteins.
The same siRNA constructs were also effective against
HBV replication in a cell line that constitutively expresses
HBV viral particles.
Klein et al. (2003) took the next step by demonstrating
that siRNAs against HBV are effective in vivo in mouse
models. First, they were able to establish mice that produce
HBsAg and HBeAg in the serum by injecting replication-
competent HBV DNA vector via the tail vein. Also, they
confirmed viral replication in hepatocytes both by RT-PCR
for viral mRNA and by staining for HBsAg and HBcAg.
When HBV vector was co-injected with siRNAs against
either the core gene or the surface protein gene, the HBsAgTarget location
ATTTGG 3V HBV polyadenylation
GGCTT 3V Pre C
GACTC 3V Surface
CCATA 3V Core
TTATG 3V Core
TGTGG 3V Core
GGACT 3V X
TCCTGAGC 3V Core
TTCGTAG 3V Surface
GCCATTTGTTC 3V Surface
CTCCCTCGCCTC 3V Core
TCCTA 3V Surface
CCAAC 3V
ATGCAA 3V
GTGAG 3V
Fig. 3. Targets that have been used against HDV. The three different RNA species (genomic RNA, antigenomic RNA, and delta antigen mRNA) that are
produced by HDVare shown. The targets that have been used against HDVare indicated as downward arrows. siRNAs directed against the regions shown with
asterisks were the most effective (Chang and Taylor, 2003).
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one-third when compared to control mice injected with just
the HBV vector. Also, they found that while the siRNA
against the surface protein gene was able to confer long-
term suppression of its target (up to 11 days), the siRNA
against the core gene had a more transient response (till 3–5
days). This again clearly shows our difficulty in predicting
the efficacy of siRNAs based on the sequence alone.
McCaffrey et al. (2003) used a plasmid-based RNAi
approach against HBV in vivo in mouse. They used seven
different targets against various regions of HBV and first
showed that except one of these shRNA-producing con-Table 3
Different targets that have been used against HDV
Target sequence Target location
5V AAGAAAGAAGUUAGAGGAACU 3V mRNA for Delta antigen
5V AAGAUAGAGGACGAAAAUCCC 3V
5V AACGGACCAGAUGGAGGUAGA 3V
5VAAGGAAGGCCCUCGAGAACAA 3V
5VAACAAGAAGAAGCAGCUAUCG 3V
5V AAGAACCUCAGCAAGGAGGAA 3V
5V AAGAGGAACUCAGGAGGUUGA 3V
5V AAGACGAGAGAAGGGAAAGAA 3V
5V AAACCAGGGAUUUCCAUAGGA 3V
5V AAAGAGCAUUGGAACGUCGGA 3V Genomic RNA
5V AAGGGUUGAGUAGCACUCAGA 3V
5V AAGCGAGGAGGAAAGCAAAGA 3V
5V AACUCGACUUAUCGUCCCCAU 3
5V AAUGCUCUUUACCGUGACAUC 3V Antigenomic RNA
5V AAGCGCCUCUUGUUCGCUGAA 3V
5V AAGUCGAGUUCCCCGGGAUAA 3V
The sequences shown in bold were able to inhibit the HDV delta antigen by
80–95% as measured by immunoblotting (Chang and Taylor, 2003). The
other sequences against the mRNA were less effective. The targets in
genomic and antigenomic RNA failed to reduce HDV RNA accumulation.structs, the others were effective in reducing the amount of
HBsAg levels in the culture medium of Huh-7 cells, which
were co-transfected with HBV producing plasmid. Two of
these shRNAs that gave more than 90% reduction after
8 days in cell culture were chosen for in vivo studies in
mice. These RNAi plasmids upon hydrodynamic injection
into the tail vein of the mice were able to suppress HBsAg,
HBcAg, and also the viral replication. However, one of these
shRNAs was shown to cause nonspecific effects in vivo.
Although this shRNA was designed to target the 3.5-kb
transcript of HBV, it also was able to suppress the 2.4- and
2.1-kb transcripts. Though this confers some sequence-
independent antiviral activity, such nonspecific effects are
least desired in RNAi-based therapy.
Giladi et al. (2003) showed that siRNAs directed against
the S gene of HBV are effective against HBV both in cell
culture and in mouse models in vivo as measured by HBV
antigen and DNA levels. They also showed that unlike
nucleoside analogues, siRNA therapy does not need active
viral replication as evidenced by the reduction in HBsAg
levels when mice were injected with replication-deficient
HBV plasmid.RNAi against hepatitis delta virus
Hepatitis delta virus (HDV) is a 1.7-kb single-stranded
circular RNA virus that replicates in the liver. Its infection in
many cases has been found to lead to chronic hepatitis and
also accounts for large cases of fulminant hepatitis (Hadler et
al., 1992). Survival of HDV requires the presence of HBsAg
supplied by simultaneous infection with HBV. In fact, the
viral envelope is mainly composed of the HBsAg and a lipid
bilayer. At least three different RNA species accumulate
S.K. Radhakrishnan et al. / Virology 323 (2004) 173–181 179during HDV replication—the genome, antigenome, and an
mRNA that codes for the delta antigen (Fig. 3).
A study by Chang and Taylor (2003) recently showed
that the delta antigen mRNA can be successfully targeted by
siRNAs in cell culture (Table 3). However, the genomic and
antigenomic RNAs are resistant to siRNA action. The
antigenome is localized in the nucleus and so could be
inaccessible for RNAi action. But the reason for the resis-
tance of genomic RNA is unclear because a large amount of
genomic RNA is cytoplasmic (Gudima et al., 2002; Mac-
naughton and Lai, 2002). The authors speculate that perhaps
the genomic RNA could be bound by host proteins, which
could protect it from RNAi action.Conclusions and future perspectives
The studies indicated in this review show that RNAi can
be used against three main hepatitis viruses—HCV,HBV, and
HDV. Both cell culture experiments and in vivo studies in
animals support this notion. While synthetic siRNAs were
able to confer a transient response, the plasmid-based
approaches have been shown to induce a more sustained
response. It has been observed that siRNAs when injected via
tail vein in mice have a high affinity to the liver (Lewis et al.,
2002; McCaffrey et al., 2002). Because the hepatitis viruses
replicate primarily in the liver of infected patients, they are
attractive targets for RNAi-based therapies. Another comple-
mentary approach that has been successful against hepatitis is
the targeting of cellular genes using RNAi. Song et al. (2003)
showed that targeting the cell-surface receptor Fas in mouse
models of autoimmune hepatitis protected it against liver
damage and fibrosis.
Contrary to what was previously thought, recent evi-
dence suggests that siRNAs and shRNAs may activate the
interferon (IFN) pathway, which usually leads to nonspe-
cific shutdown of protein synthesis and global RNA degra-
dation (Bridge et al., 2003; Sledz et al., 2003). Using
synthetic siRNAs, Bridge et al. (2003) and Sledz et al.
(2003) detected no less than a 2-fold induction of 52 well-
known IFN-induced genes and showed that this nonspecific
effect depends on the components of the IFN pathway.
Using DNA vectors that encode small RNA hairpins, Bridge
et al. (2003) showed up to 500-fold induction of 2V5V-
oligoadenylate synthetase (OAS1), a well established target
of the IFN pathway. Their data also suggest that the ability
to stimulate the IFN system depends on both the siRNA
sequence and the DNA vector used. Interestingly, in one of
the studies described in this review, siRNAs against HCV
were specifically shown not to induce the IFN pathway
(Kapadia et al., 2003). This could be explained by the
choice of cell line used, as the Huh-7 and the replicon-
containing cell lines used in these RNAi studies were
previously shown to be defective in dsRNA signaling
(Guo et al., 2003; Keskinen et al., 1999; Lanford et al.,
2003). To date, no IFN-related side effects have beenreported in vivo in animal studies that have used RNAi.
This does not mean it is not a problem in vivo, but rather
suggests that none so far have considered that possibility.
Acceptable levels of interferon system activation in a
therapeutic setting should be determined and the lowest
effective dose of siRNA should be used because it looks
plausible that the nonspecific induction of IFN by RNAi
depends on the quantity of siRNA used (Bridge et al.,
2003). Another recent finding is that RNAi may also have
IFN-independent off-target effects in certain scenarios.
Jackson et al. (2003), using a gene-expression profiling
method, found that apart from the intended target, the
siRNAs were able to suppress numerous other genes.
Scacheri et al. (2004) made the observation that different
siRNAs against the MEN1 gene were able to alter the
protein levels of p21 and p53 differently, and this effect
was found to be independent of the amount of siRNA used.
Clearly further studies are necessary to sort out the problems
of IFN-related and off-target effects before RNAi can be
extended to human patients.
As with any other therapeutic strategy, efficient delivery
presents a major obstacle before RNAi can be adapted to
clinical trials. In principle, viral vectors could be useful in
delivering shRNA-producing constructs. In the case of
siRNAs, their apparent instability in the vascular system
should be kept in mind. Chemical modifications of siRNAs
may need to be undertaken to increase their half-life.
Another approach would be to complex the siRNAs in
liposomes along with a small peptide that can bind to a
potential liver-specific receptor. Although the hydrodynamic
tail vein injection, a method where siRNAs are infused
rapidly in a volume one-tenth the mass of the animal, has
been useful in the mouse system (McCaffrey et al., 2002)
and has shown some initial promise in the case of nonhuman
primates in delivering DNA (Zhang et al., 2001), it is far
from practical in humans in a clinical setting. We will need
to draw heavily from the fields of DNA-based gene therapy
and antisense technology to address the issues of delivery.
RNAi is extremely sensitive to mismatches in the target
regions. It has been shown that as low as a single-base
mismatch can abrogate RNAi activity (Shi, 2003). It is a
serious problem when RNAi is used as a therapy because
viruses may become resistant by just altering a single
nucleotide in the target region. This is especially true in
the case of HCV where it is found that the RNA-dependent
RNA polymerase (RdRP) due to its lack of the proofreading
activity may introduce large number of errors during repli-
cation. This problem of escape viruses has been observed
before in the case of poliovirus (Gitlin et al., 2002) and more
recently for HIV (Haasnoot et al., 2003). Another possible
scenario where escape viruses may arise is when the
suppression of viral levels is not complete. For instance,
in the case of patients with chronic hepatitis C where the
circulating viral levels are between 105 and 107 genome
copies/ml of blood, even if a 90% suppression of viral RNA
is realized, it would still leave behind sufficient viral loads
S.K. Radhakrishnan et al. / Virology 323 (2004) 173–181180that are prone to becoming resistant to therapy by acquiring
mutations in the target region. Thus, it may be useful to
target more than one region by using a combination of
different siRNAs or combine different strategies such as
ribozymes and antisense oligonucleotides (for a review
comparing these different methods, see Scherer and Rossi,
2003) along with RNAi as a combined therapeutic approach
to combat the virus.References
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